Lung cancer screening is now underway to some extent in the United States, although there have been a number of publications which actually show that uptake is not very high: we’re talking in the hundreds of thousands rather than in the perhaps millions of people that might be eligible for screening. So there’s a lot of work to be done even in the United States. In Europe, here, we’re all eagerly awaiting the results of the Dutch Belgian study NELSON, and I think until that comes there’s going to be a degree of resistance into implementing it in in a wide, national way, certainly in the United Kingdom...
Lung cancer screening is now underway to some extent in the United States, although there have been a number of publications which actually show that uptake is not very high: we’re talking in the hundreds of thousands rather than in the perhaps millions of people that might be eligible for screening. So there’s a lot of work to be done even in the United States. In Europe, here, we’re all eagerly awaiting the results of the Dutch Belgian study NELSON, and I think until that comes there’s going to be a degree of resistance into implementing it in in a wide, national way, certainly in the United Kingdom. Having said that, there are nevertheless a number of pilot studies that are taking place all over the United Kingdom, and a number of other clinical trials taking place in Europe as well, to look at screening and how we can do screening well, and this is giving us a lot of information. But for the time being we are restricted to that and I think one of the biggest concerns that opponents of screening might have is the cost and the efficiency of it, and I think there are various strategies that we can put in place to try and improve that.